Context Therapeutics (CNTX) News Today → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free CNTX Stock Alerts $1.81 +0.09 (+5.23%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCNTX Stock Earnings: Context Therapeutics Beats EPS for Q1 2024investorplace.com - May 9 at 1:17 AMContext Therapeutics Reports First Quarter 2024 Operating and Financial Resultsglobenewswire.com - May 8 at 4:06 PMContext Therapeutics Raises $100 Million in Private Placement to Propel Clinical Trialsmsn.com - May 3 at 8:30 AMContext Therapeutics Secures $100 Million in Private Placement to Fuel Clinical Trialsmsn.com - May 3 at 3:29 AMWall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expectedmsn.com - May 2 at 12:28 PMContext Therapeutics Announces $100 Million Private Placementfinance.yahoo.com - May 2 at 12:28 PMContext Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76globenewswire.com - May 2 at 7:31 AMContext Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer Therapymsn.com - April 3 at 10:55 AMContext Therapeutics, Inc.cnn.com - April 2 at 3:21 PMContext Therapeutics Submits IND For CTIM-76markets.businessinsider.com - April 1 at 10:31 AMContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancersglobenewswire.com - April 1 at 7:30 AMBuy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug Positioningmarkets.businessinsider.com - March 22 at 9:32 PMCNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023investorplace.com - March 21 at 2:05 PMContext Therapeutics Inc.: Context Therapeutics Reports Full Year 2023 Operating and Financial Resultsfinanznachrichten.de - March 21 at 10:21 AMContext Therapeutics Reports Full Year 2023 Operating and Financial Resultsglobenewswire.com - March 21 at 7:43 AMContext Therapeutics Stock (NASDAQ:CNTX), Short Interest Reportbenzinga.com - December 27 at 9:11 AMContext Therapeutics Stock (NASDAQ:CNTX) Dividends: History, Yield and Datesbenzinga.com - December 27 at 9:11 AMContext Therapeutics (CNTX) Price Target Increased by 21.31% to 3.77msn.com - November 28 at 1:35 AMContext Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - November 10 at 9:33 AMContext Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024proactiveinvestors.com - November 10 at 9:33 AMContext Therapeutics GAAP EPS of -$0.37 misses by $0.06msn.com - November 9 at 11:01 PMContext Therapeutics Reports Third Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - November 9 at 6:00 PMHC Wainwright & Co. Upgrades Context Therapeutics (CNTX)msn.com - November 2 at 7:59 AMContext Therapeutics Stock (NASDAQ:CNTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 1 at 10:32 PMContext Therapeutics reveals ‘encouraging’ preclinical data for CTIM-76 tumor treatmentproactiveinvestors.com - October 31 at 3:51 PMContext Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76finance.yahoo.com - October 31 at 9:31 AMContext Therapeutics Inc. (CNTX)finance.yahoo.com - October 8 at 9:06 AMContext Therapeutics (CNTX) Price Target Increased by 45.24% to 3.11msn.com - October 5 at 8:21 AMContext Therapeutics’ Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst’s Buy Rating Perspectivemarkets.businessinsider.com - September 28 at 2:54 PMContext Therapeutics says CTIM-76 abstract accepted for presentation at SITC annual meetingproactiveinvestors.com - September 27 at 9:34 AMContext Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meetingfinance.yahoo.com - September 27 at 9:34 AMMaxim Group Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendationmsn.com - September 11 at 3:17 PMContext Therapeutics Inc.: Context Therapeutics Reports Second Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - August 17 at 2:27 AMContext Therapeutics says it has enough cash to fund operation into late 2024proactiveinvestors.com - August 16 at 5:23 AMContext Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q updatefinance.yahoo.com - August 10 at 5:48 PMContext Therapeutics Reports Second Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - August 9 at 4:46 PMContext Therapeutics to Participate in Two August 2023 Investor Conferencesfinance.yahoo.com - August 1 at 5:41 PMHC Wainwright & Co. Reiterates Context Therapeutics (CNTX) Prior Recommendationmsn.com - June 7 at 12:14 AMWill Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?finance.yahoo.com - June 3 at 10:10 AMDirector at Context Therapeutics Acquires Company Stock Options Worth 25,000 Sharesbenzinga.com - June 1 at 3:40 PMASCO 2023 Spotlight: Claudin 6 Anticipated To Shinebenzinga.com - May 16 at 5:11 PMContext Therapeutics Inc.: Context Therapeutics Reports First Quarter 2023 Operating and Financial Resultsfinanznachrichten.de - May 11 at 1:34 PMContext Therapeutics (CNTX) Gets a Hold from H.C. Wainwrightmarkets.businessinsider.com - May 11 at 8:33 AMContext Therapeutics Reports First Quarter 2023 Operating and Financial Resultsfinance.yahoo.com - May 10 at 5:32 PMContext Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meetingproactiveinvestors.com - April 24 at 9:29 AMSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Differencefinance.yahoo.com - April 18 at 1:46 PMH.C. Wainwright Remains a Hold on Context Therapeutics (CNTX)markets.businessinsider.com - April 18 at 8:06 AMContext Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinarproactiveinvestors.com - April 14 at 4:34 PMSignificant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ: CNTX) Plans To Make A Differencebenzinga.com - April 14 at 11:32 AMContext Therapeutics to Participate in Two April 2023 Investor Conferencesfinance.yahoo.com - April 3 at 8:29 AM Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: 10 CENT Crypto to Explode May 20th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career… Click For My #1 FREE Crypto for 2024 CNTX Media Mentions By Week CNTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.010.36▲Average Medical News Sentiment CNTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼60▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LVTX News MYNZ News NLSP News PHVS News PROC News QLI News TLSA News ACONW News DRTSW News ALVO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThis 1 Biotech Stock has been shocking the marketsHuge AlertsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupUrgent Nvidia WarningAltimetry348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
